Down-regulation and promoter hypermethylation are critical factors associated with PTPRG inactivation in cancer and have been observed in sporadic and Lynch syndrome colorectal cancer [9], ovarian, breast, and lung cancers [10], gastric cancer [11], chronic myeloid leukemia [12], T-cell lymphoma [13], and NPC [14]. This evidence concerns the gene PTPRG and nasopharyngeal carcinoma.